Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Biotechnology & Medical Research

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
10.62 USD -3.89% Intraday chart for Phathom Pharmaceuticals, Inc. +15.94% +16.32%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Phathom Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Phathom Pharmaceuticals Announces Voquezna® Tablets for Erosive Gerd and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients CI
Needham Raises Price Target on Phathom Pharmaceuticals to $26 From $23, Maintains Buy Rating MT
Phathom Pharmaceuticals, Inc.(NasdaqGS:PHAT) dropped from S&P Pharmaceuticals Select Industry Index CI
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD CI
Phathom Pharmaceuticals Says Erosive GERD Treatment Voquenza Commercially Available in US MT
Phathom Pharmaceuticals, Inc. Announces Commercial Availability of VOQUEZNA®? Tablets CI
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Phathom Pharmaceuticals Insider Sold Shares Worth $110,871, According to a Recent SEC Filing MT
Goldman Sachs Adjusts Price Target on Phathom Pharmaceuticals to $10 From $9, Maintains Neutral Rating MT
Transcript : Phathom Pharmaceuticals, Inc. - Special Call
Phathom Pharmaceuticals Gets FDA Approval for Voquezna Treatment DJ
Phathom Pharmaceuticals, Inc. Announces FDA Approval of VOQUEZNA® Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults CI
Phathom Pharmaceuticals Says US FDA Approves Reformulation of Vonoprazan Tablets for Helicobacter Pylori Infection MT
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for Voquezna Triple Pak (Vonoprazan, Amoxicillin, Clarithromycin) and Voquezna Dual Pak (Vonoprazan, Amoxicillin) for the Treatment of H. Pylori Infection in Adults CI
Phathom Pharmaceuticals Seeks FDA Nod for Vonoprazan to Treat Non-Erosive GERD in Adults MT
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive Germany CI
Phathom Pharmaceuticals, Inc.(NasdaqGS:PHAT) added to S&P Pharmaceuticals Select Industry Index CI
Sector Update: Health Care Stocks Gaining Late Afternoon MT
Sector Update: Health Care MT
Phathom Pharmaceuticals Submits Six-Month Stability Data to US FDA Supporting Vonoprazan for Stomach Condition MT
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
HC Wainwright Initiates Coverage on Phathom Pharmaceuticals with Buy Rating, $28 Price Target MT
Chart Phathom Pharmaceuticals, Inc.
More charts
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.62 USD
Average target price
22 USD
Spread / Average Target
+107.16%
Consensus
  1. Stock
  2. Equities
  3. Stock Phathom Pharmaceuticals, Inc. - Nasdaq
  4. News Phathom Pharmaceuticals, Inc.
  5. Phathom Pharmaceuticals Reports Wider Loss in Q2; Shares Tumble 29%